In 2022 J&J informed Emergent of its decision to terminate the deal, citing breaches including failure to supply COVID-19 vaccine drug substance on the part of the contract manufacturer.
COVID vaccine supply deal dispute: JnJ to pay USD 50 million to Emergent
Written By : Ruchika Sharma
Medically Reviewed By : Dr. Kamal Kant Kohli
Published On 2024-07-09 12:19 GMT | Update On 2024-07-16 15:35 GMT
Emergent BioSolutions has said that Johnson & Johnson has agreed to settle claims arising from the termination of the manufacturing deal for the latter's COVID-19 vaccine with a payment of USD 50 million.
Emergent had said J&J breached the agreement by failing to buy the minimum quantity of COVID-19 vaccines made by the company.
According to Reuters, under the five-year agreement , signed in 2020, Emergent would provide contract manufacturing services to produce the COVID-19 vaccine drug substance for commercial manufacturing. It was valued at about $480 million for the first two years.
The U.S. health regulator had limited the use of the J&J vaccine in 2022 due to the risk of a rare blood clotting syndrome.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd